Healthy Clinical Trial
— NUTRILEXOfficial title:
Adaptations of Exercise Energy Metabolism in Response to Simulated Weight Loss Versus Effective Weight Loss Induced by Diet in Healthy Normal Weight
More and more normal weight people are dieting in the general population. The NUTRILEX study aims to better understand the physiological adaptations in response to weight loss in healthy normal weight individuals. After an inclusion visit to verify the eligibility criteria of the subjects, they will complete a "T0" control session. The subjects will then have to complete two phases. The first transversal phase consists of 4 randomized sessions with lunch ad libitum after a physical exercise: i) a control session (no exercise, CON); ii) an exercise session at initial body weight (BWT0); iii) an exercise session with a simulated weight loss of 3% performed on an anti-gravity treadmill (BW-3%) and; iv) an exercise session with a simulated weight loss of 6% performed on an anti-gravity treadmill (BW-6%). During the second longitudinal phase, the participants will perform a dietary rebalancing and a slight caloric restriction (dietary intervention) in order to induce a weight loss of 6% of their initial body weight. Subjects will then perform an exercise session after losing 3% (T1) and then 6% (T2) of their initial body weight.
Status | Recruiting |
Enrollment | 48 |
Est. completion date | September 26, 2025 |
Est. primary completion date | September 26, 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 40 Years |
Eligibility | Inclusion Criteria: - Body mass index (BMI) between 18.5 and 24.9 kg/m², - Subjects abled to understand the information note and abled to sign the consent form, - Subjects with stable body weight (variation < 3% of body weight) until at least 6 months, - Subjects subjected to a social security plan. Non-Criteria: - Have achieved a minimal BMI < 18.5 or maximal BMI = 25 kg/m² in adult life, - Subjects with high levels of physical activity (> 5 h of exercise per week), - Presence of comorbidities or medical conditions that may interfere with study data, - Subjects undergoing energy restriction or physical activity weight loss program at the time of inclusion or within the past 6 months, - Taking medication that may interfere with study results, - Surgery within the last 3 months, - Person under guardianship, curatorship, or safeguard of justice; or not subject to a social security plan, - Pregnant or breastfeeding women, - Refusal to sign the consent form, - Person in a period of exclusion from another study, - Regular consumption of tobacco or alcohol, - Voluntary weight loss in the last 6 months, - Present or past eating disorders. |
Country | Name | City | State |
---|---|---|---|
France | CHU Clermont-Ferrand | Clermont-Ferrand | Aura |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Clermont-Ferrand |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Respiratory quotient during exercise | Respiratory quotient measured by indirect calorimetry during the low intensity exercise. | Week 1 | |
Primary | Respiratory quotient during exercise | Respiratory quotient measured by indirect calorimetry during the low intensity exercise. | Week 2 | |
Primary | Respiratory quotient during exercise | Respiratory quotient measured by indirect calorimetry during the low intensity exercise. | Week 3 | |
Primary | Respiratory quotient during exercise | Respiratory quotient measured by indirect calorimetry during the low intensity exercise. | Week 4 | |
Primary | Respiratory quotient during exercise | Respiratory quotient measured by indirect calorimetry during the low intensity exercise. | Week 8 | |
Primary | Respiratory quotient during exercise | Respiratory quotient measured by indirect calorimetry during the low intensity exercise. | Week 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |